Dynamic Monitoring of Antibody Drug Conjugates Targeting TROP2 or HER2 in Breast Cancer using Circulating Tumor Cells
Avanish Mishra, Rachel O. Abelman, Quinn E. Cunneely, Victor R. Putaturo, Akansha Deshpande, Remy Bell, Elizabeth M. Seider, Katherine H. Xu, Mythreayi Shan, J. Kelly, Shih‐Bo Huang, Olivia Rieur, Justine Knape, Kaustav A. Gopinathan, Kruthika Kikkeri, , Shyamala Maheswaran
In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.
Proceedings of the National Academy of Sciences · Jun 17, 2026Peer-reviewedCancer Biology✦ In-depth digest